Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The reporting period covers the month of February 2026, with the specific transaction date being February 25, 2026. The filing details a share repurchase executed as part of an existing buyback programme under a non-discretionary agreement with BNP Paribas SA.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share repurchases. No revenue, profit, cash flow, or debt metrics are disclosed in this specific document.
- Shares Purchased (Feb 25, 2026): 455,000 ordinary shares.
- Price Range: Lowest price paid was 2,176.00 GBp; highest price paid was 2,217.00 GBp.
- Volume-Weighted Average Price (VWAP): 2,209.58 GBp.
- Programme Progress: Since February 17, 2026, the Company has purchased 3,161,000 ordinary shares.
- Treasury Holdings: Following this purchase, GSK holds 243,052,094 ordinary shares in treasury.
- Shares in Issue: 4,073,100,332 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.97% of the total voting rights.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury stock resulting from the buyback programme. The filing confirms that the purchase was effected pursuant to a non-discretionary agreement announced on February 17, 2026. There are no other material changes to the company's financial position or operations disclosed in this text.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding future operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and the Q4 Results for 2025.
Investor Verification Checklist
- Verify the total remaining authorization under the existing buyback programme to assess future capital return capacity.
- Confirm the impact of the 5.97% treasury holding on earnings per share (EPS) calculations.
- Review the referenced 2024 Form 20-F and 2025 Q4 Results for detailed risk factors and financial performance context not included in this filing.
- Monitor subsequent filings for updates on the non-discretionary agreement with BNP Paribas SA.